Poland's national nuclear research centre — reactor safety, particle physics, advanced materials, and medical isotope production across 32 H2020 projects.
NCBJ (National Centre for Nuclear Research) is Poland's leading nuclear research institute, operating research reactors and conducting work across nuclear safety, advanced nuclear materials, particle physics, and medical isotope production. They perform fundamental research in quantum chromodynamics and neutrino physics at major international facilities (LHC, Super-Kamiokande), while simultaneously developing applied solutions for nuclear reactor safety, Generation IV reactor technologies, and radiopharmaceuticals. Their NOMATEN Centre of Excellence focuses on multifunctional materials for both industrial and medical applications, bridging the gap between nuclear science and real-world manufacturing and healthcare needs.
Core contributor across IVMR (severe accident management), NARSIS (reactor safety), SafeG (gas-cooled fast reactor safety), GEMMA/GEMINI Plus (Gen IV materials), and M4F (fusion/fission materials).
Active in HIEIC (coordinator, heavy ion collisions at LHC/RHIC), STRONG-2020 (QCD and hadron structure), SKPLUS, SK2HK, and JENNIFER/JENNIFER2 (neutrino physics with Japanese facilities).
Anchored by NOMATEN Centre of Excellence (EUR 9.86M), supported by LEU-FOREvER (research reactor fuels), ORIENT-NM (nuclear materials roadmap), M4F, and GEMMA.
PRISMAP (medical isotope production by mass separation), SINFONIA (low-dose radiation risk in medicine), and NOMATEN's radiopharmaceuticals work stream.
EU-SysFlex (pan-European flexibility services) and OneNet (unified European energy network), contributing data management and modelling expertise.
C-BORD (container inspection at border control) and Quaco (quadrupole corrector), applying detector and radiation measurement expertise to security applications.
In 2014–2018, NCBJ focused heavily on nuclear reactor safety (severe accident management, probabilistic safety assessment) and regional nuclear cooperation in Central/Eastern Europe (VINCO, BRILLIANT). From 2019 onward, the centre shifted strongly toward fundamental physics — quantum chromodynamics, hadron structure, neutrino physics — while simultaneously building up applied capabilities in medical isotopes and multifunctional materials through the flagship NOMATEN Centre of Excellence. This dual pivot toward both deeper fundamental science and translational medical/industrial applications marks a strategic broadening well beyond their earlier reactor-engineering core.
NCBJ is evolving from a reactor-safety specialist into a dual-track institute combining fundamental particle physics with translational materials science and medical isotope production — making them increasingly relevant for health-tech and advanced manufacturing partnerships.
NCBJ primarily operates as an active partner in large international consortia (23 of 32 projects as participant), but has demonstrated coordination capability on strategically important initiatives, especially in regional nuclear cooperation (VINCO) and their flagship NOMATEN centre. With 578 unique partners across 41 countries, they maintain an exceptionally wide network rather than relying on a small circle of repeat collaborators. This hub-like connectivity, combined with their willingness to join projects across diverse topics, makes them a versatile and well-connected consortium partner.
NCBJ has collaborated with 578 unique partners across 41 countries, making them one of the most broadly connected nuclear research centres in Central Europe. Their network spans from Japanese particle physics labs (Super-Kamiokande/Hyper-Kamiokande collaborations) to pan-European energy and neutron science infrastructures.
NCBJ is the only Polish institution that combines operational research reactor infrastructure with deep expertise in both nuclear engineering and fundamental particle physics at the highest international level. Their NOMATEN Centre of Excellence — the single largest H2020 investment in Polish materials science at nearly EUR 10M — positions them uniquely at the intersection of nuclear technology, advanced materials, and medical applications. For consortium builders, they offer a rare combination: Central European location (cost-effective, Widening country bonus for proposals), global-class physics capabilities, and practical nuclear engineering know-how.
